Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | PRKACG | P22612 | 1/20 | 0.31 |
| ▸ | PRKACB | P22694 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18225544 | 0.86 | PARP1 (0.31) | PARP1 | |
| SCHEMBL18248932 | 0.83 | PARP1 (0.36) | PARP1 | |
| SCHEMBL18226565 | 0.80 | CYP1A2 (0.35) | — | |
| SCHEMBL18225136 | 0.80 | PARP1 (0.37) | PARP1 | |
| SCHEMBL18225866 | 0.78 | PBK (0.40) | PRKACAPRKACGPRKACBAKT2 | |
| SCHEMBL12653269 | 0.78 | PARP1 (0.38) | PARP1 | |
| SCHEMBL12618985 | 0.78 | PARP1 (0.38) | PARP1 | |
| SCHEMBL2646903 | 0.71 | PARP1 (0.41) | PARP1PRKACA | |
| SCHEMBL663849 | 0.71 | PARP1 (0.56) | PARP1 | |
| SCHEMBL18248875 | 0.71 | PARP1 (0.40) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294732-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Gilead Sciences, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016186967-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES, INC. (US) | 2016-11-24 | — | — | WO | disclosed |